Disease management
Thesis
Validation of a Food Frequency Questionnaire assessing the sugar intakes of Pacific Islanders in Auckland, New Zealand
Background: Evidence linking fructose intakes to gout, type 2 diabetes and obesity is growing. This is of particular interest in Pacific people who have higher rates of these diseases compared to other ethnic groups in New Zealand.
Thesis
Early Life Risk Factors for Overweight and Obesity in Childhood
Background: Prevalence of childhood overweight and obesity has risen dramatically over the last few decades, suggesting a causative role for environmental factors, including activity, diet and eating behaviours.Objectives: To determine the prevalence, change in prevalence and degree of tracking of overweight and obesity in a birth cohort of Dunedin children from age three to seven...
Thesis
The role of SLC2A9 Variants in Hyperuricemia and Gout
Gout is a debilitating arthritis caused by elevated levels of serum urate in the blood (hyperuricemia). The prevalence of gout is on the rise worldwide with particularly high rates of the disease present in Māori and Pacific populations in New Zealand (9.3-13.9% of Māori men and 14.9% of Pacific Island men affected). Genetic and environmental...
Thesis
Outcomes of a Community-Based Rehabilitation Programme for People with Diabetes/Prediabetes
Aim: Diabetes is a chronic condition that requires ongoing healthcare management and is increasing in prevalence. Exercise is known to be effective in diabetes management as well as ongoing patient education and support. The aim of this study was to investigate the qualitative and quantitative outcome data of an existing 12-week community-based rehabilitation programme for...
Thesis
Negotiating Barriers: An Investigation of Early Access to Rheumatology Services for Patients with Inflammatory Arthritis in the Wellington Region
Inflammatory arthritis (IA) is term that encompasses a range of auto-immune joint diseases that can cause severe pain, joint erosion and disability. Although there is no cure for these IAs, early treatment beginning within three months of symptom onset with disease-modifying anti-rheumatic drugs can significantly improve patient outcomes (Combe et al., 2007; Dixon Woods, et...